synjardyhcp.com Report : Visit Site

Technical data of the synjardyhcp.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host synjardyhcp.com. Currently, hosted in United Kingdom and its service provider is Datapipe .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.2.15 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

this site makes heavy use of javascript either you have javascript disabled or your browser does not support javascript. to work properly, this page requires javascript to be enabled. if you can enable it in your browser's preferences, you may have a better experience. ") ") you are now leaving a boehringer ingelheim pharmaceuticals, inc. (bipi) and lilly usa, llc (lilly) site. bipi and lilly are not responsible for the way information is processed by sites linked to this one. please review those sites' privacy policies and terms of use to understand how your information will be processed. linking to any other site is at your own risk. ok cancel for us healthcare professionals menu close important safety information other empagliflozin products for patients prescribing information synjardy synjardy xr jardiance patient labeling synjardy synjardy xr jardiance close important safety information other empagliflozin products for patients synjardy prescribing information including boxed warning synjardy xr prescribing information including boxed warning synjardy medication guide synjardy xr medication guide jardiance prescribing information jardiance patient information available in once-daily extended release for adults with type 2 diabetes, along with diet and exercise to improve glycemic control synjardy offers the active ingredient of jardiance ® (empagliflozin) and metformin in a single pill learn more about the active ingredient of jardiance to initiate synjardy or synjardy xr, determine appropriate combination of the active ingredient of jardiance and metformin* synjardy synjardy xr jardiance 10 mg/day metformin 1000 mg/day metformin 2000 mg/day choose appropriate starting dose synjardy 5 mg/500 mg synjardy 5 mg/1000 mg jardiance 25 mg/day metformin 1000 mg/day metformin 2000 mg/day choose appropriate starting dose synjardy 12.5 mg/500 mg synjardy 12.5 mg/1000 mg jardiance 10 mg/day metformin 1000 mg/day metformin 2000 mg/day choose appropriate starting dose synjardy xr 10 mg/1000 mg synjardy xr 5 mg/1000 mg 2 tablets once daily jardiance 25 mg/day metformin 1000 mg/day metformin 2000 mg/day choose appropriate starting dose synjardy xr 25 mg/1000 mg synjardy xr 12.5 mg/1000 mg 2 tablets once daily *in patients switching from separate tablets of jardiance and metformin to synjardy, administer the same daily doses already prescribed. in patients switching to synjardy xr, administer the same daily dose of jardiance and a similar daily dose of metformin. synjardy and synjardy xr should be taken with meals no dose adjustment needed if egfr ≥45 ml/min/1.73 m 2 . assess renal function prior to initiating synjardy or synjardy xr and periodically thereafter synjardy and synjardy xr are contraindicated in patients with moderate to severe renal impairment (egfr <45 ml/min/1.73 m 2 ), end-stage renal disease, or dialysis; acute or chronic metabolic acidosis, including diabetic ketoacidosis; and history of serious hypersensitivity reaction to empagliflozin or metformin before initiating synjardy or synjardy xr in patients with volume depletion, volume status should be assessed and corrected synjardy or synjardy xr may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures a lower dose of insulin or insulin secretagogues (eg, sus) may be required to reduce the risk of hypoglycemia when synjardy or synjardy xr are used in combination with these agents with synjardy or synjardy xr, dose escalation should be gradual to reduce the gastrointestinal side effects associated with metformin use egfr=estimated glomerular filtration rate; su=sulfonylurea. expand important safety information warning: lactic acidosis with synjardy and synjardy xr postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/ml. risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information. if lactic acidosis is suspected, discontinue synjardy or synjardy xr and institute general supportive measures in a hospital setting. prompt hemodialysis is recommended. indications and limitations of use for jardiance, synjardy, and synjardy xr jardiance is indicated to reduce the risk of cardiovascular (cv) death in adults with type 2 diabetes mellitus and established cv disease. jardiance, synjardy, and synjardy xr are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. synjardy and synjardy xr are indicated when both empagliflozin and metformin hydrochloride are appropriate. empagliflozin, a component of synjardy and synjardy xr , is indicated to reduce the risk of cv death in adults with type 2 diabetes mellitus and established cv disease. however, the effectiveness of synjardy and synjardy xr on reducing the risk of cv death in adults with type 2 diabetes mellitus and cv disease has not been established. limitations of use jardiance, synjardy, and synjardy xr are not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. contraindications jardiance history of serious hypersensitivity to empagliflozin or any of the excipients in jardiance ; severe renal impairment, end-stage renal disease, or dialysis. synjardy and synjardy xr : moderate to severe renal impairment (egfr <45 ml/min/1.73 m2), end-stage renal disease, or dialysis; acute or chronic metabolic acidosis, including diabetic ketoacidosis; history of serious hypersensitivity reaction to empagliflozin, metformin, or any of the excipients in synjardy and synjardy xr . warnings and precautions lactic acidosis: synjardy, synjardy xr there have been cases of metformin-associated lactic acidosis, including fatal cases. these cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension, and resistant bradyarrhythmias have occurred with severe acidosis. additional findings included elevated blood lactate concentrations (>5 mmol/l), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio, metformin plasma levels generally >5 mcg/ml. if lactic acidosis is suspected, immediately discontinue synjardy or synjardy xr and institute general supportive measures promptly in a hospital setting. prompt hemodialysis is recommended to correct the acidosis. educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue synjardy or synjardy xr and promptly notify their healthcare provider. recommendations to reduce the risk include: renal impairment: obtain egfr prior to initiating and annually or more frequently in patients at increased risk of developing renal impairment. drug interactions: more frequent monitoring is recommended when administered with drugs that impair renal function, result in hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. age 65 or greater: assess renal function more frequently. radiological studies with contrast: stop synjardy or synjardy xr at the time of, or prior to, an iodinated contrast imaging procedure in patients with an egfr of 45-60 ml/min/1.73m2; patients with a history of hepatic impairment, alcoholism or heart failure; or patients who will be administered intra-arterial iodinated contrast. re-evaluate egfr 48 hours after the procedure and restart synjardy or synjardy xr if renal function is stable. surgery and other procedures: discontinue while patients have restricted food and fluid intake. hypoxic states: discontinue in conditions associated with hypoxemia. excessive alcohol intake: warn patients against excessive alcohol intake. hepatic impairment: avoid use in patients with hepatic disease. hypotension: jardiance, synjardy, synjardy xr empagliflozin causes intravascular volume contraction and symptomatic hypotension may occur. before initiating, assess and correct volume status in the elderly, and in patients with renal impairment, low systolic blood pressure, or on diuretics. monitor for hypotension. ketoacidosis: jardiance, synjardy, synjardy xr ketoacidosis, a serious life-threatening condition requiring urgent hospitalization has been identified in patients with type 1 and type 2 diabetes mellitus receiving sglt2 inhibitors, including empagliflozin. fatal cases of ketoacidosis have been reported in patients taking empagliflozin. patients who present with signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, even if blood glucose levels are less than 250 mg/dl. if suspected, discontinue, evaluate, and treat promptly. before initiating, consider risk factors for ketoacidosis. patients may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. acute kidney injury and impairment in renal function: jardiance, synjardy, synjardy xr empagliflozin causes intravascular volume contraction and can cause renal impairment. acute kidney injury requiring hospitalization and dialysis have been identified in patients taking sglt2 inhibitors, including empagliflozin; some reports involved patients younger than 65 years of age. before initiating, consider factors that may predispose patients to acute kidney injury. consider temporary discontinuation in settings of reduced oral intake or fluid losses. monitor patients for signs and symptoms of acute kidney injury. if it occurs, discontinue and treat promptly. empagliflozin increases serum creatinine and decreases egfr. patients with hypovolemia may be more susceptible to these changes. before initiating, evaluate renal function and monitor thereafter. more frequent monitoring is recommended in patients with egfr <60 ml/min/1.73 m 2 . discontinue in patients with a persistent egfr <45 ml/min/1.73 m 2 . urosepsis and pyelonephritis: jardiance, synjardy, synjardy xr serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving sglt2 inhibitors, including empagliflozin. treatment with sglt2 inhibitors increases the risk of urinary tract infections. evaluate for signs and symptoms of urinary tract infections and treat promptly. hypoglycemia: jardiance, synjardy, synjardy xr the use in combination with insulin or insulin secretagogues can increase the risk of hypoglycemia. a lower dose of insulin or the insulin secretagogue may be required. hypoglycemia could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation or during concomitant use of synjardy or synjardy xr with other glucose-lowering agents or with the use of ethanol. genital mycotic infections: jardiance, synjardy, synjardy xr empagliflozin increases the risk of genital mycotic infections, especially in patients with prior infections. monitor and treat as appropriate. hypersensitivity reactions: jardiance, synjardy and synjardy xr discontinue jardiance, synjardy or synjardy xr , treat promptly, and monitor until signs and symptoms resolve. vitamin b 12 deficiency: synjardy, synjardy xr metformin may lower vitamin b12 levels. monitor hematologic parameters annually for patients on synjardy or synjardy xr . increased low-density lipoprotein cholesterol (ldl-c): jardiance, synjardy, synjardy xr monitor and treat as appropriate. macrovascular outcomes: synjardy, synjardy xr there have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with synjardy or synjardy xr . most common adverse reactions (≥5%) jardiance: urinary tract infections and female genital mycotic infections. synjardy and synjardy xr: urinary tract infections and female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. drug interactions empagliflozin: coadministration with diuretics may enhance the potential for volume depletion. metformin hydrochloride: more frequent monitoring is recommended when synjardy or synjardy xr is administered with drugs that impair renal function, result in hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. drugs that reduce metformin clearance such as ranolazine, vandetanib, dolutegravir, or cimetidine may increase the accumulation of metformin and increase the risk of lactic acidosis. consider the benefits and risks of concomitant use. carbonic anhydrase inhibitors: the concomitant use of carbonic anhydrase inhibitors (e.g., topiramate) and metformin may increase the risk of lactic acidosis. consider more frequent monitoring. alcohol: alcohol is known to potentiate the effect of metformin on lactate metabolism. warn patients against excessive alcohol intake while taking synjardy or synjardy xr . use in special populations pregnancy: jardiance, synjardy, and synjardy xr are not recommended, especially during the second and third trimesters. with synjardy or synjardy xr , discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin may result in ovulation in some anovulatory women. lactation: jardiance, synjardy, and synjardy xr are not recommended while breastfeeding. geriatric use: jardiance, synjardy, and synjardy xr are expected to have diminished efficacy in elderly patients with renal impairment. renal function should be assessed more frequently in elderly patients. dose selection should be cautious, starting at the lowest dose. the incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥75 years treated with empagliflozin. indications and limitations of use for jardiance, synjardy, and synjardy xr jardiance is indicated to reduce the risk of cv death in adults with type 2 diabetes mellitus and established cv disease. jardiance, synjardy and synjardy xr are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. synjardy and synjardy xr are indicated when both empagliflozin and metformin hydrochloride are appropriate. empagliflozin, a component of synjardy and synjardy xr , is indicated to reduce the risk of cardiovascular (cv) death in adults with type 2 diabetes mellitus and established cv disease. however, the effectiveness of synjardy and synjardy xr on reducing the risk of cv death in adults with type 2 diabetes mellitus and cv disease has not been established. limitations of use jardiance, synjardy, and synjardy xr are not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. cl-jar-100006 12.19.17 please see synjardy prescribing information , including boxed warning regarding lactic acidosis, and medication guide . please see synjardy xr prescribing information , including boxed warning regarding lactic acidosis, and medication guide . please see jardiance prescribing information and patient information . privacy statement terms of use contact us working hard to make our medicines available to people who need them. visit site> synjardy, synjardy xr, and jardiance are registered trademarks of boehringer ingelheim international gmbh & co. kg and used under license. use of this site is subject to the internet site legal notices and disclaimers and privacy statement. copyright © 2018 boehringer ingelheim pharmaceuticals, inc. all rights reserved. (01/18) pc-03324-r2 working hard to make our medicines available to people who need them. visit site>

URL analysis for synjardyhcp.com

https://www.synjardyhcp.com/#panel2
https://www.synjardyhcp.com/#panel1

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: SYNJARDYHCP.COM
Registry Domain ID: 2012397479_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corehub.net
Registrar URL: http://corehub.net
Updated Date: 2018-03-14T08:12:47Z
Creation Date: 2016-03-15T07:30:10Z
Registry Expiry Date: 2020-03-15T07:30:10Z
Registrar: Corehub, S.R.L.
Registrar IANA ID: 15
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +34935275235
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS2.OBSERVATOIREDESMARQUES.FR
Name Server: NS3.NAMESHIELD.NET
Name Server: OBS.NS1.FR
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-06-12T17:21:30Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Corehub, S.R.L.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =synjardyhcp.com

  PORT 43

  TYPE domain

DOMAIN

  NAME synjardyhcp.com

  CHANGED 2018-03-14

  CREATED 2016-03-15

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS2.OBSERVATOIREDESMARQUES.FR 80.74.69.8

  NS3.NAMESHIELD.NET 45.63.17.113

  OBS.NS1.FR 81.92.84.146

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .